Naldemedine - Shionogi

Drug Profile

Naldemedine - Shionogi

Alternative Names: Rizmoic; S-297995; Symproic

Latest Information Update: 12 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Shionogi
  • Developer Purdue Pharma; Shionogi
  • Class Small molecules
  • Mechanism of Action Opioid mu receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Constipation

Most Recent Events

  • 12 Jul 2018 Naldemedine - Shionogi is available for licensing as of 09 Jul 2018. http://www.shionogi.co.jp/en/ 9244787
  • 09 Jul 2018 Shionogi and Purdue Pharma terminate the agreement for joint commercialisation of naldemedine in USA
  • 06 Mar 2018 Updated adverse events data from the phase III trial in Constipation released by Shionogi
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top